(Q33753486)

29 July 2017

1 reference

title

Teratogen update: thalidomide: a review, with a focus on ocular findings and new potential uses (English)

1 reference

29 July 2017

0 references

Miller MT

1

1 reference

29 July 2017

Strömland K

series ordinal

2

1 reference

29 July 2017

publication date

1 November 1999

1 reference

Birth Defects Research Part A: Clinical and Molecular Teratology

29 July 2017

published in

1 reference

29 July 2017

volume

60

1 reference

29 July 2017

issue

5

1 reference

29 July 2017

page(s)

306-321

1 reference

A prospective trial of thalidomide for the treatment of HIV-associated idiopathic esophageal ulcers

29 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-9926%28199911%2960%3A5%3C306%3A%3AAID-TERA11%3E3.0.CO%3B2-Y

Was tumour necrosis factor-alpha responsible for the fetal malformations associated with thalidomide in the early 1960s?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-9926%28199911%2960%3A5%3C306%3A%3AAID-TERA11%3E3.0.CO%3B2-Y

21 January 2018

Safety of thalidomide

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-9926%28199911%2960%3A5%3C306%3A%3AAID-TERA11%3E3.0.CO%3B2-Y

HIV wasting syndrome: treatment update

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-9926%28199911%2960%3A5%3C306%3A%3AAID-TERA11%3E3.0.CO%3B2-Y

Clinical and basic science lessons from the thalidomide tragedy: what have we learned about the causes of limb defects?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-9926%28199911%2960%3A5%3C306%3A%3AAID-TERA11%3E3.0.CO%3B2-Y

Thalidomide in dermatology. New indications for an old drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-9926%28199911%2960%3A5%3C306%3A%3AAID-TERA11%3E3.0.CO%3B2-Y

Thalidomide, a current teratogen in South America

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-9926%28199911%2960%3A5%3C306%3A%3AAID-TERA11%3E3.0.CO%3B2-Y

21 January 2018

Safety of thalidomide

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-9926%28199911%2960%3A5%3C306%3A%3AAID-TERA11%3E3.0.CO%3B2-Y

OCULAR DEFECTS IN THALIDOMIDE BABIES.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-9926%28199911%2960%3A5%3C306%3A%3AAID-TERA11%3E3.0.CO%3B2-Y

Thalidomide is an inhibitor of angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-9926%28199911%2960%3A5%3C306%3A%3AAID-TERA11%3E3.0.CO%3B2-Y

Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-9926%28199911%2960%3A5%3C306%3A%3AAID-TERA11%3E3.0.CO%3B2-Y

Clinical experience with thalidomide in the management of severe oral and genital ulceration in conditions such as Behçet's disease: use of neurophysiological studies to detect thalidomide neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-9926%28199911%2960%3A5%3C306%3A%3AAID-TERA11%3E3.0.CO%3B2-Y

Angiogenesis as a target for tumor treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-9926%28199911%2960%3A5%3C306%3A%3AAID-TERA11%3E3.0.CO%3B2-Y

Ocular anomalies in association with developmental limb abnormalities of drug origin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-9926%28199911%2960%3A5%3C306%3A%3AAID-TERA11%3E3.0.CO%3B2-Y

Thalidomide for systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-9926%28199911%2960%3A5%3C306%3A%3AAID-TERA11%3E3.0.CO%3B2-Y

An open study of pentoxyfylline and thalidomide as adjuvant therapy in the treatment of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-9926%28199911%2960%3A5%3C306%3A%3AAID-TERA11%3E3.0.CO%3B2-Y

Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-9926%28199911%2960%3A5%3C306%3A%3AAID-TERA11%3E3.0.CO%3B2-Y

Thalidomide as an anti-TNF-alpha inhibitor: implications for clinical use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-9926%28199911%2960%3A5%3C306%3A%3AAID-TERA11%3E3.0.CO%3B2-Y

The effect of thalidomide on the pathogenesis of human immunodeficiency virus type 1 and M. tuberculosis infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-9926%28199911%2960%3A5%3C306%3A%3AAID-TERA11%3E3.0.CO%3B2-Y

Thalidomide in the treatment of sixty cases of chronic discoid lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-9926%28199911%2960%3A5%3C306%3A%3AAID-TERA11%3E3.0.CO%3B2-Y

Thalidomide inhibits corneal angiogenesis induced by vascular endothelial growth factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-9926%28199911%2960%3A5%3C306%3A%3AAID-TERA11%3E3.0.CO%3B2-Y

[Langerhans histiocytosis in adults: cutaneous and mucous lesion regression after treatment with thalidomide].

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-9926%28199911%2960%3A5%3C306%3A%3AAID-TERA11%3E3.0.CO%3B2-Y

Incidence of malformations since the introduction of thalidomide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-9926%28199911%2960%3A5%3C306%3A%3AAID-TERA11%3E3.0.CO%3B2-Y

Die Thalidomid-Embryopathie*

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-9926%28199911%2960%3A5%3C306%3A%3AAID-TERA11%3E3.0.CO%3B2-Y

A short history of thalidomide embryopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-9926%28199911%2960%3A5%3C306%3A%3AAID-TERA11%3E3.0.CO%3B2-Y

THALIDOMIDE AND CONGENITAL ABNORMALITIES

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-9926%28199911%2960%3A5%3C306%3A%3AAID-TERA11%3E3.0.CO%3B2-Y

21 January 2018

Thalidomide embryopathy

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-9926%28199911%2960%3A5%3C306%3A%3AAID-TERA11%3E3.0.CO%3B2-Y

Cell type-/inducer-specific bidirectional regulation by thalidomide and phenylphthalimides of tumor necrosis factor-alpha production and its enantio-dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-9926%28199911%2960%3A5%3C306%3A%3AAID-TERA11%3E3.0.CO%3B2-Y

Thalidomide and thalidomide analogs reduce HIV type 1 replication in human macrophages in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-9926%28199911%2960%3A5%3C306%3A%3AAID-TERA11%3E3.0.CO%3B2-Y

Down-regulation of adhesion receptors on cells of primate embryos as a probable mechanism of the teratogenic action of thalidomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-9926%28199911%2960%3A5%3C306%3A%3AAID-TERA11%3E3.0.CO%3B2-Y

Thalidomide as treatment of refractory aphthous ulceration related to human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-9926%28199911%2960%3A5%3C306%3A%3AAID-TERA11%3E3.0.CO%3B2-Y

Congenital crocodile tears: a key to the aetiology of Duane's syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-9926%28199911%2960%3A5%3C306%3A%3AAID-TERA11%3E3.0.CO%3B2-Y

Inflammatory bowel disease management. Some thoughts on future drug developments

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-9926%28199911%2960%3A5%3C306%3A%3AAID-TERA11%3E3.0.CO%3B2-Y

Long-term thalidomide use in refractory cutaneous lesions of systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-9926%28199911%2960%3A5%3C306%3A%3AAID-TERA11%3E3.0.CO%3B2-Y

Hydrolysis of thalidomide abrogates its ability to enhance mononuclear cell synthesis of IL-2 as well as its ability to suppress the synthesis of TNF-alpha.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-9926%28199911%2960%3A5%3C306%3A%3AAID-TERA11%3E3.0.CO%3B2-Y

The treatment of lepra reaction in lepromatous leprosy. Fifteen years' experience with thalidomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-9926%28199911%2960%3A5%3C306%3A%3AAID-TERA11%3E3.0.CO%3B2-Y

Defects and Disabilities of Thalidomide Children

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-9926%28199911%2960%3A5%3C306%3A%3AAID-TERA11%3E3.0.CO%3B2-Y

Thalidomide treatment of mucosal ulcerations in HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-9926%28199911%2960%3A5%3C306%3A%3AAID-TERA11%3E3.0.CO%3B2-Y

Proposed mechanisms of action in thalidomide embryopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-9926%28199911%2960%3A5%3C306%3A%3AAID-TERA11%3E3.0.CO%3B2-Y

Refractive evaluation in thalidomide embryopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-9926%28199911%2960%3A5%3C306%3A%3AAID-TERA11%3E3.0.CO%3B2-Y

Thalidomide embryopathy: revisited 27 years later

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-9926%28199911%2960%3A5%3C306%3A%3AAID-TERA11%3E3.0.CO%3B2-Y

Thalidomide reduces tumour necrosis factor-alpha production by human alveolar macrophages.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-9926%28199911%2960%3A5%3C306%3A%3AAID-TERA11%3E3.0.CO%3B2-Y

Tumor necrosis factor: a pleiotropic cytokine and therapeutic target

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-9926%28199911%2960%3A5%3C306%3A%3AAID-TERA11%3E3.0.CO%3B2-Y

Rediscovering thalidomide: a review of its mechanism of action, side effects, and potential uses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-9926%28199911%2960%3A5%3C306%3A%3AAID-TERA11%3E3.0.CO%3B2-Y

Binding of thalidomide to alpha1-acid glycoprotein may be involved in its inhibition of tumor necrosis factor alpha production

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-9926%28199911%2960%3A5%3C306%3A%3AAID-TERA11%3E3.0.CO%3B2-Y

Why I doubted that thalidomide was the cause of the epidemic of limb defects of 1959 to 1961.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-9926%28199911%2960%3A5%3C306%3A%3AAID-TERA11%3E3.0.CO%3B2-Y

The return of thalidomide: are birth defects surveillance systems ready?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-9926%28199911%2960%3A5%3C306%3A%3AAID-TERA11%3E3.0.CO%3B2-Y

Ocular malformations caused by thalidomide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-9926%28199911%2960%3A5%3C306%3A%3AAID-TERA11%3E3.0.CO%3B2-Y

10.1002/(SICI)1096-9926(199911)60:5<306::AID-TERA11>3.0.CO;2-Y

21 January 2018

Identifiers

DOI

1 reference

29 July 2017

1 reference